Peptide Therapeutics: Current Status And Future Directions
Protein–protein interactions (PPIs) execute many fundamental cellular functions and have served as prime drug targets over the last two decades. Interfering intracellular PPIs with small molecules has been extremely difficult for larger or flat binding sites, as antibodies cannot cross the cell membrane to reach such target sites.
In recent years, peptides smaller size and balance of conformational rigidity and flexibility have made them promising candidates for targeting challenging binding interfaces with satisfactory binding affinity and specificity. In contrast to antibodies, they are small in size, easy to synthesize and have the ability to penetrate the cell membranes. They are naturally occurring biologics and hence safer than synthetic drugs and have a greater efficacy, selectivity and specificity. In contrast to synthetic substances, peptides are degraded into their component proteinogenic amino acids without leading to toxic metabolites. With the advances in recombinant protein expression technologies, the development of more efficient and economic peptide synthesis, the improvement of peptide purification systems and new analytical tools, more peptide drugs have been developed and entered clinical use.
Currently, there are more than 60 approved peptide medicines on the market in the United States and this is expected to grow significantly, with approximately ∼200 peptide drugs in clinical development, and ∼600 in the preclinical drug discovery stage. Peptide drugs cover a wide range of therapeutic areas, such as diabetics, cancer, osteoporosis, hormone therapy, cardiovascular diseases, anemia, bowel syndrome, Cushing’s disease, multiple sclerosis, HIV, and many more. The focus of peptide drugs is shifting from hormone therapy and diagnosis to cancer and infection.
TargetMol’s peptide products collect most approved peptide drugs and anti-bacterial active peptides, and other different peptide hormones, hormone analogs, enzymes, peptide receptors, cytokines, Tag peptides, etc.
Click to download：Peptide Therapeutics
We believe that with the help of our fast and efficient global supply chain, professional and rigorous procurement process, and timely dynamic products, you will save more time for less cost and lead in both biology research and early drug discovery and screening. For more informations, you can visit www.targetmol.com Our email address: email@example.com(US Customer) or firstname.lastname@example.org(International Customer).
36 Washington Street, Wellesley Hills, Massachusetts, 02481